ଆଟୋରଭାଷ୍ଟାଟିନ/ପେରିଣ୍ଡୋପ୍ରିଲ/ଆମ୍ଲୋଡିପିନ

ଆଟୋରଭାଷ୍ଟାଟିନ/ପେରିଣ୍ଡୋପ୍ରିଲ/ଆମ୍ଲୋଡିପିନ
Combination of
Atorvastatin	Statin
Perindopril	ACE inhibitor
Amlodipine	Calcium channel blocker
Clinical data
Trade names	Valongix; Stapressial; Lipertance; Triveram; others
Routes of; administration	By mouth

ଆଟୋରଭାଷ୍ଟାଟିନ/ପେରିଣ୍ଡୋପ୍ରିଲ/ଆମ୍ଲୋଡିପିନ ହେଉଛି ଏକ ମିଶ୍ରିତ ଔଷଧ ଯାହା ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ଉଚ୍ଚ କୋଲେଷ୍ଟେରୋଲ କିମ୍ବା ହୃଦରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୩] ଏହା ହୃଦରୋଗର ବିପଦକୁ ପ୍ରାୟ ୫୦% ହ୍ରାସ କରିପାରେ । ^[୩] ଗୋଟିଏ ବଟିକାର ଲାଭ ହେଉଛି ଲୋକମାନେ ଏହାକୁ ଖାଇବାକୁ ଅଧିକ ଇଚ୍ଛୁକ ହୁଅନ୍ତି । ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୨]

ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ପୃଥକ ଉପାଦାନଗୁଡ଼ିକ ଉପରେ ନିର୍ଭର କରେ ଏବଂ ସାଧାରଣତଃ କମ୍ ଥାଏ ।^[୩] ଆମ୍ଲୋଡିପିନ୍ ଯୋଗୁଁ ହେଉଥିବା ଗୋଡ଼ ଫୁଲାକୁ ପେରିଣ୍ଡୋପ୍ରିଲ୍ କମାଇପାରେ ।^[୩] ଏହା ଆଟୋରଭାଷ୍ଟାଟିନ ଯାହା ଏକ ଷ୍ଟାଟିନ; ପେରିଣ୍ଡୋପ୍ରିଲ ଯାହା ଏକ ଏସିଇ ଇନହିବିଟର ଏବଂ ଆମ୍ଲୋଡିପିନ ଯାହା ଏକ କ୍ୟାଲସିୟମ ଚ୍ୟାନେଲ ବ୍ଲକର୍ ତିନି ଔଷଧର ଏକ ମିଶ୍ରଣ । ^[୩]

୨୦୨୧ ସୁଦ୍ଧା ଅନେକ ୟୁରୋପୀୟ ଦେଶରେ ଏହି ମିଶ୍ରଣ ଅନୁମୋଦିତ ହୋଇଛି ।^[୧] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକ ଔଷଧ ତାଲିକାରେ ଲିପିବଦ୍ଧ ଅଛି।^[୪] ଏହା ଏକ ପ୍ରକାରର ପଲିପିଲ୍ (polypill) ।^[୩] ଆଶା କରାଯାଉଛି ଯେ ମିଶ୍ରିତ ଔଷଧର ମୂଲ୍ୟ ପୃଥକ ଉପାଦାନ ତୁଳନାରେ କମ୍ ହେବ, କିନ୍ତୁ ଏହା ଦେଶ ଅନୁସାରେ ଭିନ୍ନ ହୋଇପାରେ ।^[୫] ^[୬] ୨୦୨୦ ମସିହାରେ ମରିସସରେ ଏକ ମାସର ଔଷଧର ମୂଲ୍ୟ ପ୍ରାୟ ୨୬ ଆମେରିକୀୟ ଡଲାର ଥିଲା ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "List of nationally authorised medicinal products" (PDF). EMA. Archived (PDF) from the original on 3 March 2022. Retrieved 18 September 2023.
↑ ^୨.୦ ^୨.୧ "European Medicines Agency decision P/0300/2013" (PDF). EMA. Archived (PDF) from the original on 19 September 2023. Retrieved 18 September 2023.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ Bertrand, ME; Vlachopoulos, C; Mourad, JJ (August 2016). "Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine". American journal of cardiovascular drugs : drugs, devices, and other interventions. 16 (4): 241–253. doi:10.1007/s40256-016-0175-2. PMID 27256435.
↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
↑ Stafylas, P.; Karaiskou, M.; Zouka, M. (October 2018). "PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING". Value in Health. 21: S99–S100. doi:10.1016/j.jval.2018.09.590. Archived from the original on 19 October 2023. Retrieved 24 September 2023.
↑ ^୬.୦ ^୬.୧ "An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults" (PDF). WHO. Archived (PDF) from the original on 19 October 2023. Retrieved 24 September 2023.

[EMA2021-1] ୧.୦ ^୧.୧ "List of nationally authorised medicinal products" (PDF). EMA. Archived (PDF) from the original on 3 March 2022. Retrieved 18 September 2023.

[EMA2013-2] ୨.୦ ^୨.୧ "European Medicines Agency decision P/0300/2013" (PDF). EMA. Archived (PDF) from the original on 19 September 2023. Retrieved 18 September 2023.

[Ber2016-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ Bertrand, ME; Vlachopoulos, C; Mourad, JJ (August 2016). "Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine". American journal of cardiovascular drugs : drugs, devices, and other interventions. 16 (4): 241–253. doi:10.1007/s40256-016-0175-2. PMID 27256435.

[WHO23rd-4] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[5] Stafylas, P.; Karaiskou, M.; Zouka, M. (October 2018). "PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING". Value in Health. 21: S99–S100. doi:10.1016/j.jval.2018.09.590. Archived from the original on 19 October 2023. Retrieved 24 September 2023.

[App2023-6] ୬.୦ ^୬.୧ "An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults" (PDF). WHO. Archived (PDF) from the original on 19 October 2023. Retrieved 24 September 2023.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]